Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2023 04:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Board of Directors and Board Committee Membership

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) refers to its announcement...
May 10, 2023 04:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that...
April 17, 2023 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. , April 17, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its New Drug...
April 11, 2023 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated...
April 11, 2023 04:30 ET | Source: HUTCHMED (China) Limited

Intended Retirement of Independent Non-executive Director

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr...
April 04, 2023 05:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the...
March 30, 2023 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib...
March 14, 2023 09:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its...
March 12, 2023 20:07 ET | Source: HUTCHMED (China) Limited

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it...
February 28, 2023 03:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full...